US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% NVDA $215.38 ▼-1.17% GOOGL $324.89 ▲+1.34% MSFT $531.01 ▼-0.06% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66%
FinancialContent

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

50.84 -0.04 (-0.07%)
Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
News headline image
Earnings Preview For Travere Therapeutics ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in Japan 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics ↗
 
Via Benzinga
News headline image
Where Travere Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Travere Therapeutics Provides Corporate Update and 2024 Outlook
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug ↗
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
News headline image
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
What's Going On With Travere Therapeutics Stock? ↗
Travere Therapeutics, Inc. (NASDAQ: TVTX) shares are trading higher Tuesday. 
Via Benzinga
News headline image
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday. 
Via Benzinga
Topics Stocks
News headline image
Crude Oil Moves Lower; AutoZone Profit Tops Views ↗
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500... 
Via Benzinga
Topics Stocks
News headline image
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
Travere Therapeutics Inc. (NASDAQ: TVTX) Near the Top of Equities by Percentage Gain on 12/5
Via Investor Brand Network
News headline image
Where Travere Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
NIO Reports Q3 Results, Joins Hovnanian Enterprises, Signet Jewelers And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded mostly lower, with the Dow Jones index falling more than 100 points on Tuesday. 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Preview: Travere Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Third Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For November 7, 2023 ↗
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Travere Therapeutics to Report Third Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties ↗
San Diego, CA -- (SBWIRE) -- 09/29/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Travere Therapeutics, Inc. 
Via SBWire
News headline image
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
From Travere Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >